Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Fast and simple biomarker detection by computational microscopy

Project description

Leveraging 3D light diffraction via computational microscopy for biomarker detection

Changes in the concentrations of biomolecules circulating in the blood are indicative of metabolic processes relevant to health and disease. Reducing the cost, time and manual labour required to detect low concentrations of biomarkers could substantially expand access, improving disease diagnosis and monitoring and thus human health and quality of life. Funded by the European Research Council, the BioMarkerFlow project aims to optimise its fast, simple and accurate biomarker detection method based on computational microscopy, leveraging the so-called point spread function. The system will be optimised in the context of minimising the adverse effects of a cell-based cancer treatment, namely cytokine production, which can be debilitating and even life-threatening.

Objective

Detection of low concentrations of biomarkers, such as low-abundant proteins in physiological samples, is crucial for early-stage diagnosis and disease monitoring. However, existing detection methods are often laborious, costly, and time consuming, rendering them unsuitable for such applications. Based on advances in computational PSF engineering microscopy made during our ERC Starting Grant, and in combination with microfluidic design, we developed a simple and fast biomarker detection method which allows accurate and sensitive results with minimal hands-on sample processing, which we have validated for potential applicability in diagnostics, and specifically, for continuous monitoring.
As a target clinical application towards which we can optimize our engineering efforts, we demonstrate the potential for preventative diagnostics via a collaboration with Rambam Medical Center (Israel), focusing on monitoring cell-based cancer treatments. While cell-based therapies can be highly effective, they have introduced new types of cytokine-related adverse effects that can be debilitating and even life threatening. Due to the current lack of appropriate diagnostics for preventative treatment, these adverse effects are mitigated only when symptoms arise, which might be too late. We hypothesize that earlier detection using our method will enable preventive treatment and reduction in frequency and severity of these adverse events, transforming patient outcome. We will develop a multiplexed cytokine detection scheme that reaches clinically significant sensitivity, and assess the effectiveness of this approach by monitoring CAR-T patients. In the duration of the project, we will conduct a market research and develop regulation strategy with the aid of industrial and medical collaborations, advancing our diagnostic method toward commercialization.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Net EU contribution
€ 150 000,00
Address
SENATE BUILDING TECHNION CITY
32000 Haifa
Israel
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)